vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and IT TECH PACKAGING, INC. (ITP). Click either name above to swap in a different company.
IT TECH PACKAGING, INC. is the larger business by last-quarter revenue ($25.6M vs $21.9M, roughly 1.2× Cue Biopharma, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -5.7%, a 12.9% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 2.1%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 10.5%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
IT TECH PACKAGING, INC. is a paper manufacturing enterprise primarily operating in China. It produces and distributes a diverse portfolio of paper products including corrugated packaging paper, boxboard, and printing-use cultural paper, serving sectors such as consumer goods packaging, logistics, and commercial printing across its core market.
CUE vs ITP — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $25.6M |
| Net Profit | $1.6M | $-1.4M |
| Gross Margin | — | 7.9% |
| Operating Margin | 9.0% | -3.9% |
| Net Margin | 7.2% | -5.7% |
| Revenue YoY | 1292.3% | 2.1% |
| Net Profit YoY | 116.7% | 26.6% |
| EPS (diluted) | $0.05 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | — | ||
| Q3 25 | $2.1M | $25.6M | ||
| Q2 25 | $3.0M | $24.8M | ||
| Q1 25 | $421.0K | $10.9M | ||
| Q4 24 | $1.6M | $17.6M | ||
| Q3 24 | $3.3M | $25.1M | ||
| Q2 24 | $2.7M | $26.2M | ||
| Q1 24 | $1.7M | $6.9M |
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-7.4M | $-1.4M | ||
| Q2 25 | $-8.5M | $-2.0M | ||
| Q1 25 | $-12.3M | $-3.5M | ||
| Q4 24 | — | $-4.0M | ||
| Q3 24 | $-8.7M | $-2.0M | ||
| Q2 24 | $-10.2M | $-77.7K | ||
| Q1 24 | $-12.3M | $-3.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | 7.9% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | — | 7.6% | ||
| Q2 24 | — | 12.4% | ||
| Q1 24 | — | 5.8% |
| Q4 25 | 9.0% | — | ||
| Q3 25 | -353.4% | -3.9% | ||
| Q2 25 | -292.3% | -7.1% | ||
| Q1 25 | -2921.4% | -31.0% | ||
| Q4 24 | — | -21.5% | ||
| Q3 24 | -264.2% | -5.8% | ||
| Q2 24 | -390.6% | 2.1% | ||
| Q1 24 | -737.8% | -51.0% |
| Q4 25 | 7.2% | — | ||
| Q3 25 | -346.6% | -5.7% | ||
| Q2 25 | -287.1% | -7.9% | ||
| Q1 25 | -2911.4% | -32.2% | ||
| Q4 24 | — | -22.9% | ||
| Q3 24 | -259.6% | -7.9% | ||
| Q2 24 | -382.7% | -0.3% | ||
| Q1 24 | -719.1% | -54.6% |
| Q4 25 | $0.05 | — | ||
| Q3 25 | $-0.07 | $-0.11 | ||
| Q2 25 | $-0.09 | $-0.16 | ||
| Q1 25 | $-0.17 | $-0.35 | ||
| Q4 24 | — | $-0.40 | ||
| Q3 24 | $-0.17 | $-0.20 | ||
| Q2 24 | $-0.20 | $-0.01 | ||
| Q1 24 | $-0.25 | $-0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | — |
| Total DebtLower is stronger | — | $4.7M |
| Stockholders' EquityBook value | $26.4M | $152.0M |
| Total Assets | $42.2M | $175.7M |
| Debt / EquityLower = less leverage | — | 0.03× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | — | ||
| Q3 25 | $11.7M | — | ||
| Q2 25 | $27.5M | — | ||
| Q1 25 | $13.1M | — | ||
| Q4 24 | $22.5M | — | ||
| Q3 24 | $32.4M | — | ||
| Q2 24 | $30.0M | — | ||
| Q1 24 | $41.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $4.7M | ||
| Q2 25 | — | $4.7M | ||
| Q1 25 | — | $4.7M | ||
| Q4 24 | — | $4.7M | ||
| Q3 24 | $1.0M | $8.9M | ||
| Q2 24 | $2.0M | $11.3M | ||
| Q1 24 | $3.0M | $11.4M |
| Q4 25 | $26.4M | — | ||
| Q3 25 | $13.2M | $152.0M | ||
| Q2 25 | $18.2M | $152.3M | ||
| Q1 25 | $6.6M | $152.8M | ||
| Q4 24 | $17.5M | $156.1M | ||
| Q3 24 | $25.4M | $164.3M | ||
| Q2 24 | $21.6M | $163.5M | ||
| Q1 24 | $30.0M | $164.3M |
| Q4 25 | $42.2M | — | ||
| Q3 25 | $31.6M | $175.7M | ||
| Q2 25 | $40.7M | $175.2M | ||
| Q1 25 | $22.3M | $175.2M | ||
| Q4 24 | $32.2M | $177.5M | ||
| Q3 24 | $44.8M | $190.0M | ||
| Q2 24 | $42.3M | $191.4M | ||
| Q1 24 | $54.0M | $177.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.03× | ||
| Q2 25 | — | 0.03× | ||
| Q1 25 | — | 0.03× | ||
| Q4 24 | — | 0.03× | ||
| Q3 24 | 0.04× | 0.05× | ||
| Q2 24 | 0.09× | 0.07× | ||
| Q1 24 | 0.10× | 0.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $1.5M |
| Free Cash FlowOCF − Capex | — | $1.5M |
| FCF MarginFCF / Revenue | — | 5.9% |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | -0.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $3.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | — | ||
| Q3 25 | $-9.0M | $1.5M | ||
| Q2 25 | $-3.4M | $1.4M | ||
| Q1 25 | $-8.2M | $-2.5M | ||
| Q4 24 | $-36.3M | $3.5M | ||
| Q3 24 | $-7.5M | $1.5M | ||
| Q2 24 | $-10.0M | $721.9K | ||
| Q1 24 | $-9.8M | $624.4K |
| Q4 25 | — | — | ||
| Q3 25 | — | $1.5M | ||
| Q2 25 | $-3.4M | $1.3M | ||
| Q1 25 | $-8.3M | $-2.5M | ||
| Q4 24 | $-36.4M | $3.5M | ||
| Q3 24 | $-7.5M | $1.2M | ||
| Q2 24 | $-10.0M | $668.3K | ||
| Q1 24 | $-9.8M | $615.4K |
| Q4 25 | — | — | ||
| Q3 25 | — | 5.9% | ||
| Q2 25 | -116.5% | 5.4% | ||
| Q1 25 | -1976.7% | -22.8% | ||
| Q4 24 | -2309.3% | 19.6% | ||
| Q3 24 | -225.7% | 4.9% | ||
| Q2 24 | -376.2% | 2.5% | ||
| Q1 24 | -573.0% | 9.0% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.9% | 0.1% | ||
| Q1 25 | 35.6% | 0.1% | ||
| Q4 24 | 4.2% | 0.1% | ||
| Q3 24 | 0.0% | 1.0% | ||
| Q2 24 | 0.4% | 0.2% | ||
| Q1 24 | 3.2% | 0.1% |
| Q4 25 | -0.68× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
ITP
Segment breakdown not available.
